Asunto(s)
Acarbosa/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Digoxina/sangre , Insuficiencia Cardíaca/tratamiento farmacológico , Inositol/análogos & derivados , Anciano , Anciano de 80 o más Años , Cardiotónicos/sangre , Cardiotónicos/farmacocinética , Cardiotónicos/uso terapéutico , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/complicaciones , Digoxina/farmacocinética , Digoxina/uso terapéutico , Interacciones Farmacológicas , Inhibidores Enzimáticos/uso terapéutico , Inhibidores de Glicósido Hidrolasas , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/complicaciones , Humanos , Hipoglucemiantes/uso terapéutico , Inositol/uso terapéutico , MasculinoRESUMEN
The compound 1-phenyl-5-vinylimidazolidine-2-thione was previously reported to be the causative agent in the outbreak referred to as Spanish toxic oil syndrome. X-ray crystallography, together with nuclear magnetic resonance and infra-red spectroscopy, now show the correct structure of this compound to be N-(5-vinyl-1,3-thiazolidin-2-ylidene)phenylamine (5-VTPA). Data for the structural characterization of 5-VTPA and the closely related isomer N-(4-vinyl-1,3-thiazolidin-2-ylidene)phenylamine are reported.
Asunto(s)
Brassica , Aceites de Plantas/envenenamiento , Tiazoles/aislamiento & purificación , Cristalografía , Ácidos Grasos Monoinsaturados , Espectroscopía de Resonancia Magnética , Estructura Molecular , Aceite de Brassica napus , Análisis Espectral , Síndrome , TiazolidinasRESUMEN
The antihypertensive effect of a new calcium antagonist, nicardipine hydrochloride (YC-93), was studied in 47 mild to moderate essential hypertensives. YC-93 (30-60 mg/day) was administered orally alone for 8 weeks (Group I, 31 patients) or in combination with diuretics, beta blockers, or both (Group II, 16 patients). Blood pressure was reduced from 173.6 +/- 2.2/103.5 +/- 1.7 to 139.7 +/- 2.0/87.2 +/- 1.1 mmHg in Group I and from 172.9 +/- 3.9/108.9 +/- 2.9 to 140.5 +/- 2.3/89.5 +/- 2.5 mm Hg in Group II. Pulse rate was not altered in Group I but increased transiently in Group II. The side effects seen in seven patients were mostly related to the vasodilatation and were generally transient and mild. These results indicate that YC-93 is an effective antihypertensive drug for the treatment of essential hypertension.
Asunto(s)
Hipertensión/tratamiento farmacológico , Nifedipino/uso terapéutico , Piridinas/uso terapéutico , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Femenino , Humanos , Hipertensión/sangre , Masculino , Persona de Mediana Edad , Nicardipino , Nifedipino/efectos adversos , Nifedipino/análogos & derivados , Pulso Arterial , Renina/sangre , Factores de TiempoRESUMEN
A case of vitamin D resistant hypophosphatemic osteomalacia associated with osteosarcoma of the mandible is presented. The patient complained of lumbar, knee and foot pain and muscle weakness of two years' duration. Serum phosphorous was 1.0-1.6 mg/dl, tubular reabsorption of phosphorus was 47 to 58%, TmPO4/GFR was o.7-1.2 mg/dl. Aminoaciduria was noted. Bone biopsy confirmed the diagnosis of osteomalacia. He partially responded to the treatment with 1 alpha()H) D3 and sodium phosphate. After removal of sarcoma of the mandible, symptoms remitted and pertinent laboratory data became normal except serum alkaline phosphatase for more than one year without treatment. It is suggested that an impaired response of the tubule and bone to active vitamin D3, caused in some way by the osteosarcoma might be one of the causes of osteomalacia in this case.